Rodman & Renshaw Outperform On Curis, Inc.

Rodman & Renshaw has an Outperform rating and a $6 price target on shares of Curis, Inc. CRIS. In a note to clients, Rodman & Renshaw writes, "We are reiterating our Market Outperform / Speculative Risk rating and a 12-month target price of $6. Our price target is derived from a comparables analysis with other similarly staged biotechnology companies, in addition to an NPV analysis of the BCC revenue potential. Today's top-line pivotal study results, taken together with a prior Phase 1 trial evaluating vismodegib that yielded a 55% response rate in 33 advanced BCC patients, as well as highly statistically significant results from a randomized Phase 2 trial evaluating vismodegib in Gorlin syndrome, collectively establish a profile of a highly efficacious inhibitor for a range of BCC patients." At last check, shares of CRIS were up 2 cents to $3.34.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyHealth CareRodman & Renshaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!